Aequitas Research

Hong Jie Seow

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

Independent Insight Provider

IPOs and Placements coverage across Asia Pacific

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Integris Medtech Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/integris-medtech-limited" target="_blank" data-smartkarma-citation="entities:45943:1" rel="noopener">Integris Medtech Limited (1234518D IN)</a> is looking to raise about US$340m in its upcoming India IPO. The deal will be run by ICICI, Axis, Citi and IIFL.</li>
<li>Integris Medtech Limited is a diversified India-based global MedTech company engaged in the development, manufacturing, and commercialization of medical devices and laboratory solutions.</li>
<li>The Lab Solutions segment provides laboratory and clinical diagnostic products across hospitals and industrial labs. The Cardiovascular segment focuses on interventional cardiology devices used treatments of coronary artery disease.</li>
</ul>



Integris Medtech Limited (1234518D IN) is looking to raise about US$340m in its upcoming India IPO. The deal will be run by ICICI, Axis, Citi and IIFL.
Integris Medtech Limited is a diversified India-based global MedTech company engaged in the development, manufacturing, and commercialization of medical devices and laboratory solutions.
The Lab Solutions segment provides laboratory and clinical diagnostic products across hospitals and industrial labs. The Cardiovascular segment focuses on interventional cardiology devices used treatments of coronary artery disease.


Integris Medtech Limited Pre-IPO Tearsheet